Related Experiment Video
Updated: May 20, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
[Screen of phosphopeptide specific for acute leukemia]
Hong-ling Peng1, Chong-wen Dai, Guang-sen Zhang
1Central South University, Changsha, China.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|July 12, 2012
Summary
Researchers identified specific phosphopeptides for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). These findings may aid in diagnosing and treating acute leukemia.
Area of Science:
- Biochemistry
- Oncology
- Proteomics
Context:
- Acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), presents a significant challenge in diagnosis and treatment.
- Identifying specific biomarkers is crucial for targeted therapies and improved patient outcomes.
Purpose:
- To screen for phosphopeptides that are specific to acute leukemia subtypes.
- To investigate the expression of various phosphopeptides in patients with ALL and AML.
Summary:
- Mononuclear cells from 16 ALL and 20 AML patients were analyzed using immunoprecipitation and LC-MS.
- Key findings include the widespread expression of non-receptor tyrosine kinases (Fyn, Yes, Src) in acute leukemia.
- Specific phosphopeptides, including Abl/iso1, Abl, Bcr, JNK2, JNK2 iso2, Cas-L, Cbl, CrkL, CENTD1, ZO2, GFR-1, and SHIP-2, were detected in Ph-positive ALL.
- Hck, Lyn, and Fgr were selectively expressed in AML (excluding AML-M3).
Impact:
- The identified phosphopeptides show potential as diagnostic markers for specific subtypes of acute leukemia.
- These phosphopeptide signatures may offer novel therapeutic targets for acute leukemia.
- This research contributes to a deeper understanding of the molecular landscape of acute leukemias.
